Antiviral, HIV fusion inhibitor, Anti-CD4 antibody
Disease
HIV-1 infection [DS:H01563]
Comment
Monoclonal antibody
Treatment of HIV/AIDS in HIV-1 infected patients
Target
CD4 [HSA:920] [KO:K06454]
Pathway
hsa03250
Viral life cycle - HIV-1
hsa04060
Cytokine-cytokine receptor interaction
hsa04514
Cell adhesion molecules
hsa04660
T cell receptor signaling pathway
hsa05170
Human immunodeficiency virus 1 infection
Structure map
map07053
Anti-HIV agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AX Other antivirals
J05AX23 Ibalizumab
D09575 Ibalizumab (USAN/INN) <US>
USP drug classification [BR:br08302]
Antivirals
Anti-HIV Agents, Other
Ibalizumab
D09575 Ibalizumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD4
D09575 Ibalizumab (USAN/INN) <US>
Antimicrobials [BR:br08307]
Antivirals
Entry, fusion or uncoating inhibitor
CD4 antibody
D09575 Ibalizumab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09575
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09575
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09575